Kristine A. Smith
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kristine A. Smith has a total of 356 co-authors. Here are the top co-authors by number of shared publications:
- Jeremiah A. Alt
Department of Otolaryngology—Head and Neck Surgery University of Utah Salt Lake City Utah USA
12 shared publications - Amber U. Luong
The University of Texas Health Science Center at Houston
5 shared publications - Joshua M. Levy
Division of Intramural Research, National Institute on Deafness and Other Communication Disorders (NIDCD), National Institutes of Health
5 shared publications Sarah K. Wise
Department of Otolaryngology–Head and Neck Surgery Emory University School of Medicine Atlanta Georgia USA
5 shared publicationsGretchen Oakley
University of Utah Salt Lake City UT
4 shared publicationsRichard R. Orlandi
Division of Otolaryngology-Head and Neck Surgery, University of Utah, Salt Lake City, UT
4 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 2 January 2024
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 14 (2) , 149-608
International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors
Background: Sinonasal neoplasms, whether benign and malignant, pose a significant challenge to clinicians and represent a model area for multidisciplinary collaboration in order to optimize patient care. The International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors (ICSNT) aims to summarize the best available evidence and presents 48 thematic and histopathology‐based topics spanning the field.Methods: In accordance with prior International Consensus Statement on Allergy and Rhinology documents, ICSNT assigned each topic as an Evidence‐Based Review with Recommendations, Evidence‐Based Review, and Literature Review based on the level of evidence. An international group of multidisciplinary author teams were assembled for the topic reviews using the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses format, and completed sections underwent a thorough and iterative consensus‐building process. The final document underwent rigorous synthesis and review prior to publication.Results: The ICSNT document consists of four major sections: general principles, benign neoplasms and lesions, malignant neoplasms, and quality of life and surveillance. It covers 48 conceptual and/or histopathology‐based topics relevant to sinonasal neoplasms and masses. Topics with a high level of evidence provided specific recommendations, while other areas summarized the current state of evidence. A final section highlights research opportunities and future directions, contributing to advancing knowledge and community intervention.Conclusion: As an embodiment of the multidisciplinary and collaborative model of care in sinonasal neoplasms and masses, ICSNT was designed as a comprehensive, international, and multidisciplinary collaborative endeavor. Its primary objective is to summarize the existing evidence in the field of sinonasal neoplasms and masses.
- 2 January 2024
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 14 (2) , 149-608
Top Cited PapersOpen AccessInternational Consensus Statement on Allergy and Rhinology: Sinonasal Tumors
Background: Sinonasal neoplasms, whether benign and malignant, pose a significant challenge to clinicians and represent a model area for multidisciplinary collaboration in order to optimize patient care. The International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors (ICSNT) aims to summarize the best available evidence and presents 48 thematic and histopathology‐based topics spanning the field.Methods: In accordance with prior International Consensus Statement on Allergy and Rhinology documents, ICSNT assigned each topic as an Evidence‐Based Review with Recommendations, Evidence‐Based Review, and Literature Review based on the level of evidence. An international group of multidisciplinary author teams were assembled for the topic reviews using the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses format, and completed sections underwent a thorough and iterative consensus‐building process. The final document underwent rigorous synthesis and review prior to publication.Results: The ICSNT document consists of four major sections: general principles, benign neoplasms and lesions, malignant neoplasms, and quality of life and surveillance. It covers 48 conceptual and/or histopathology‐based topics relevant to sinonasal neoplasms and masses. Topics with a high level of evidence provided specific recommendations, while other areas summarized the current state of evidence. A final section highlights research opportunities and future directions, contributing to advancing knowledge and community intervention.Conclusion: As an embodiment of the multidisciplinary and collaborative model of care in sinonasal neoplasms and masses, ICSNT was designed as a comprehensive, international, and multidisciplinary collaborative endeavor. Its primary objective is to summarize the existing evidence in the field of sinonasal neoplasms and masses.
- Top Cited PapersOpen Access
- 6 March 2023
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 13 (4) , 293-859
International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Background: In the 5 years that have passed since the publication of the 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR‐Allergic Rhinitis 2018), the literature has expanded substantially. The ICAR‐Allergic Rhinitis 2023 update presents 144 individual topics on allergic rhinitis (AR), expanded by over 40 topics from the 2018 document. Originally presented topics from 2018 have also been reviewed and updated. The executive summary highlights key evidence‐based findings and recommendation from the full document.Methods: ICAR‐Allergic Rhinitis 2023 employed established evidence‐based review with recommendation (EBRR) methodology to individually evaluate each topic. Stepwise iterative peer review and consensus was performed for each topic. The final document was then collated and includes the results of this work.Results: ICAR‐Allergic Rhinitis 2023 includes 10 major content areas and 144 individual topics related to AR. For a substantial proportion of topics included, an aggregate grade of evidence is presented, which is determined by collating the levels of evidence for each available study identified in the literature. For topics in which a diagnostic or therapeutic intervention is considered, a recommendation summary is presented, which considers the aggregate grade of evidence, benefit, harm, and cost.Conclusion: The ICAR‐Allergic Rhinitis 2023 update provides a comprehensive evaluation of AR and the currently available evidence. It is this evidence that contributes to our current knowledge base and recommendations for patient evaluation and treatment.
- 6 March 2023
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 13 (4) , 293-859
Top Cited PapersOpen AccessInternational consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Background: In the 5 years that have passed since the publication of the 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR‐Allergic Rhinitis 2018), the literature has expanded substantially. The ICAR‐Allergic Rhinitis 2023 update presents 144 individual topics on allergic rhinitis (AR), expanded by over 40 topics from the 2018 document. Originally presented topics from 2018 have also been reviewed and updated. The executive summary highlights key evidence‐based findings and recommendation from the full document.Methods: ICAR‐Allergic Rhinitis 2023 employed established evidence‐based review with recommendation (EBRR) methodology to individually evaluate each topic. Stepwise iterative peer review and consensus was performed for each topic. The final document was then collated and includes the results of this work.Results: ICAR‐Allergic Rhinitis 2023 includes 10 major content areas and 144 individual topics related to AR. For a substantial proportion of topics included, an aggregate grade of evidence is presented, which is determined by collating the levels of evidence for each available study identified in the literature. For topics in which a diagnostic or therapeutic intervention is considered, a recommendation summary is presented, which considers the aggregate grade of evidence, benefit, harm, and cost.Conclusion: The ICAR‐Allergic Rhinitis 2023 update provides a comprehensive evaluation of AR and the currently available evidence. It is this evidence that contributes to our current knowledge base and recommendations for patient evaluation and treatment.
- Open Access
- 5 July 2022
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 12 (10) , 1225-1231
Indications for absorbable steroid‐eluting sinus implants: Viewpoint via the Delphi method
Absorbable steroid‐eluting sinus implants provide targeted corticosteroid release over a sustained period and are designed to prevent both undesirable adhesion formation and sinus ostia restenosis. Here, we highlight the key evidence of these implants to date and query a group of experts via a Delphi process on the indications and optimal timing for intraoperative or in‐office placement of these implants. Six of a total of 12 statements reached consensus and were accepted. Overall, experts largely agree that intraoperative or in‐office use of steroid‐eluting stents could be considered for patients: (1) who are diabetic or intolerant of oral steroids, (2) undergoing extended frontal sinus surgery, and (3) with recurrent stenosis. Given the lack of expert consensus on other key statements, clinicians should carefully consider these treatment options on a case‐by‐case basis after shared decision‐making.
- 5 July 2022
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 12 (10) , 1225-1231
Open AccessIndications for absorbable steroid‐eluting sinus implants: Viewpoint via the Delphi method
Absorbable steroid‐eluting sinus implants provide targeted corticosteroid release over a sustained period and are designed to prevent both undesirable adhesion formation and sinus ostia restenosis. Here, we highlight the key evidence of these implants to date and query a group of experts via a Delphi process on the indications and optimal timing for intraoperative or in‐office placement of these implants. Six of a total of 12 statements reached consensus and were accepted. Overall, experts largely agree that intraoperative or in‐office use of steroid‐eluting stents could be considered for patients: (1) who are diabetic or intolerant of oral steroids, (2) undergoing extended frontal sinus surgery, and (3) with recurrent stenosis. Given the lack of expert consensus on other key statements, clinicians should carefully consider these treatment options on a case‐by‐case basis after shared decision‐making.
- 30 October 2021
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 12 (2) , 141-146
What is allergic fungal sinusitis: A call to action
- 30 October 2021
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 12 (2) , 141-146
What is allergic fungal sinusitis: A call to action
- Open Access
- 11 July 2021
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 11 (11) , 1524-1528
Biologics for chronic rhinosinusitis with nasal polyps: Economics and ethics
Summary: Biologics have recently been approved for use in chronic rhinosinusitis with nasal polyps patients. While effective in controlling disease on subjective and objective short‐term outcome measures, limited data suggest that biologics have the potential to be used long term. The current wholesale acquisition costs for biologics are quite high. Widespread, prolonged use of these medications may create a large burden to our healthcare system. Cost‐effectiveness analyses, particularly for specific patient cohorts, are needed to determine appropriate use of these medications. The ethics of patient preference of various treatment options, counseling regarding side effect profiles, and healthcare economics also need to be addressed.
- 11 July 2021
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 11 (11) , 1524-1528
Open AccessBiologics for chronic rhinosinusitis with nasal polyps: Economics and ethics
Summary: Biologics have recently been approved for use in chronic rhinosinusitis with nasal polyps patients. While effective in controlling disease on subjective and objective short‐term outcome measures, limited data suggest that biologics have the potential to be used long term. The current wholesale acquisition costs for biologics are quite high. Widespread, prolonged use of these medications may create a large burden to our healthcare system. Cost‐effectiveness analyses, particularly for specific patient cohorts, are needed to determine appropriate use of these medications. The ethics of patient preference of various treatment options, counseling regarding side effect profiles, and healthcare economics also need to be addressed.
- 24 February 2021
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 11 (8) , 1197-1206
Asthma increases long‐term revision rates of endoscopic sinus surgery in chronic rhinosinusitis with and without nasal polyposis
Background: Chronic rhinosinusitis with asthma (CRS‐A) has a significant impact on patient morbidity and quality of life. Nevertheless, little is known about the natural history of endoscopic sinus surgery (ESS) in this cohort. The objective of this study was to evaluate revision rates of ESS in CRS‐A and identify risk factors associated with increased likelihood for revision surgery compared to those with CRS without asthma (CRS‐alone).Methods: The Utah Population Database was queried for patients age >18 years with CRS who underwent at least 1 ESS between 1996 and 2018. Demographic information and history of ESS were collected and compared between CRS‐A and CRS‐alone using chi‐square tests for categorical variables and t tests for continuous variables. Risk factors for revision surgery were analyzed using Cox proportional hazard models.Results: A total of 33,090 patients (7693 CRS‐A and 25,397 CRS‐alone) were included in the final analysis. Mean follow up was 9.8 years in CRS‐A and 9.1 years in CRS‐alone (p < 0.001). The revision rate among patients with CRS‐A (21.5%) was twice that of CRS‐alone (10.8%) (p < 0.001). Among patients with CRS, a history of allergy (p < 0.001), asthma (p < 0.001), and nasal polyposis (p < 0.001) was independently associated with increased risk of revision ESS. Patients with CRS‐A and nasal polyposis were 6 times more likely to require revision surgery than those with CRS‐alone (p < 0.010).Conclusion: The rate of revision ESS in CRS‐A was twice that of CRS‐alone; patients with CRS‐A and nasal polyposis were 6 times more likely to require revision than those with CRS‐alone. ©2021 ARSAAOA, LLC.
- 24 February 2021
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 11 (8) , 1197-1206
Asthma increases long‐term revision rates of endoscopic sinus surgery in chronic rhinosinusitis with and without nasal polyposis
Background: Chronic rhinosinusitis with asthma (CRS‐A) has a significant impact on patient morbidity and quality of life. Nevertheless, little is known about the natural history of endoscopic sinus surgery (ESS) in this cohort. The objective of this study was to evaluate revision rates of ESS in CRS‐A and identify risk factors associated with increased likelihood for revision surgery compared to those with CRS without asthma (CRS‐alone).Methods: The Utah Population Database was queried for patients age >18 years with CRS who underwent at least 1 ESS between 1996 and 2018. Demographic information and history of ESS were collected and compared between CRS‐A and CRS‐alone using chi‐square tests for categorical variables and t tests for continuous variables. Risk factors for revision surgery were analyzed using Cox proportional hazard models.Results: A total of 33,090 patients (7693 CRS‐A and 25,397 CRS‐alone) were included in the final analysis. Mean follow up was 9.8 years in CRS‐A and 9.1 years in CRS‐alone (p < 0.001). The revision rate among patients with CRS‐A (21.5%) was twice that of CRS‐alone (10.8%) (p < 0.001). Among patients with CRS, a history of allergy (p < 0.001), asthma (p < 0.001), and nasal polyposis (p < 0.001) was independently associated with increased risk of revision ESS. Patients with CRS‐A and nasal polyposis were 6 times more likely to require revision surgery than those with CRS‐alone (p < 0.010).Conclusion: The rate of revision ESS in CRS‐A was twice that of CRS‐alone; patients with CRS‐A and nasal polyposis were 6 times more likely to require revision than those with CRS‐alone. ©2021 ARSAAOA, LLC.
- Open Access
- 1 January 2021
- Published by SAGE Publications in Journal of Otolaryngology - Head & Neck Surgery
- Vol. 50 (1) , 1-6
Virtual Care in Rhinology
Background: The SARS-CoV-2 (COVID) pandemic has resulted in an increase in virtual care. While some specialties are well suited to virtual care, Otolaryngology – Head and Neck Surgery could be limited due to reliance on physical examination and nasal endoscopy, including Rhinology. It is likely virtual care will remain integrated for the foreseeable future and it is important to determine the strengths and weaknesses of this treatment modality for rhinology. Methods: A survey on virtual care in rhinology was distributed to 61 Canadian rhinologists. The primary objective was to determine how virtual care compared to in-person care in each area of a typical appointment. Other areas focused on platforms used to deliver virtual care and which patients could be appropriately assessed by virtual visits. Results: 43 participants responded (response rate 70.5%). The majority of participants use the telephone as their primary platform. History taking and reviewing results (lab work, imaging) were reported to be equivalent in virtual care. Non-urgent follow up and new patients were thought to be the most appropriate for virtual care. The inability to perform exams and nasal endoscopy were reported to be significant limitations. Conclusion: It is important to understand the strengths and limitations of virtual care. These results identify the perceived strengths and weaknesses of virtual care in rhinology, and will help rhinologists understand the role of virtual care in their practices. Graphical
- 1 January 2021
- Published by SAGE Publications in Journal of Otolaryngology - Head & Neck Surgery
- Vol. 50 (1) , 1-6
Open AccessVirtual Care in Rhinology
Background: The SARS-CoV-2 (COVID) pandemic has resulted in an increase in virtual care. While some specialties are well suited to virtual care, Otolaryngology – Head and Neck Surgery could be limited due to reliance on physical examination and nasal endoscopy, including Rhinology. It is likely virtual care will remain integrated for the foreseeable future and it is important to determine the strengths and weaknesses of this treatment modality for rhinology. Methods: A survey on virtual care in rhinology was distributed to 61 Canadian rhinologists. The primary objective was to determine how virtual care compared to in-person care in each area of a typical appointment. Other areas focused on platforms used to deliver virtual care and which patients could be appropriately assessed by virtual visits. Results: 43 participants responded (response rate 70.5%). The majority of participants use the telephone as their primary platform. History taking and reviewing results (lab work, imaging) were reported to be equivalent in virtual care. Non-urgent follow up and new patients were thought to be the most appropriate for virtual care. The inability to perform exams and nasal endoscopy were reported to be significant limitations. Conclusion: It is important to understand the strengths and limitations of virtual care. These results identify the perceived strengths and weaknesses of virtual care in rhinology, and will help rhinologists understand the role of virtual care in their practices. Graphical
- 4 December 2020
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 11 (5) , 941-945
Characterizing the complexity of frontal endoscopic sinus surgery: a multi‐institutional, prospective, observational trial
- 4 December 2020
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 11 (5) , 941-945
Characterizing the complexity of frontal endoscopic sinus surgery: a multi‐institutional, prospective, observational trial
- Top Cited PapersOpen Access
- 24 November 2020
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 11 (3) , 213-739
International consensus statement on allergy and rhinology: rhinosinusitis 2021
I. Executive Summary: Background: The 5 years since the publication of the first International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR‐RS) has witnessed foundational progress in our understanding and treatment of rhinologic disease. These advances are reflected within the more than 40 new topics covered within the ICAR‐RS‐2021 as well as updates to the original 140 topics. This executive summary consolidates the evidence‐based findings of the document.Methods: ICAR‐RS presents over 180 topics in the forms of evidence‐based reviews with recommendations (EBRRs), evidence‐based reviews, and literature reviews. The highest grade structured recommendations of the EBRR sections are summarized in this executive summary.Results: ICAR‐RS‐2021 covers 22 topics regarding the medical management of RS, which are grade A/B and are presented in the executive summary. Additionally, 4 topics regarding the surgical management of RS are grade A/B and are presented in the executive summary. Finally, a comprehensive evidence‐based management algorithm is provided.Conclusion: This ICAR‐RS‐2021 executive summary provides a compilation of the evidence‐based recommendations for medical and surgical treatment of the most common forms of RS.
- 24 November 2020
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 11 (3) , 213-739
Top Cited PapersOpen AccessInternational consensus statement on allergy and rhinology: rhinosinusitis 2021
I. Executive Summary: Background: The 5 years since the publication of the first International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR‐RS) has witnessed foundational progress in our understanding and treatment of rhinologic disease. These advances are reflected within the more than 40 new topics covered within the ICAR‐RS‐2021 as well as updates to the original 140 topics. This executive summary consolidates the evidence‐based findings of the document.Methods: ICAR‐RS presents over 180 topics in the forms of evidence‐based reviews with recommendations (EBRRs), evidence‐based reviews, and literature reviews. The highest grade structured recommendations of the EBRR sections are summarized in this executive summary.Results: ICAR‐RS‐2021 covers 22 topics regarding the medical management of RS, which are grade A/B and are presented in the executive summary. Additionally, 4 topics regarding the surgical management of RS are grade A/B and are presented in the executive summary. Finally, a comprehensive evidence‐based management algorithm is provided.Conclusion: This ICAR‐RS‐2021 executive summary provides a compilation of the evidence‐based recommendations for medical and surgical treatment of the most common forms of RS.
- 1 June 2020
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 10 (7) , 856-870
Drug‐eluting implants in chronic rhinosinusitis: an evidence‐based review with recommendations
Background: Drug‐eluting implants are becoming increasingly popular in the treatment of chronic rhinosinusitis (CRS). A previous attempt to make an evidence‐based recommendation was hindered by limited evidence and experience with these implants. Since that time, the body of literature discussing drug‐eluting implants has grown rapidly. The objective of this study was to review drug‐eluting implants designed for use in the sinonasal cavity through an evidence‐based review with recommendations.Methods: A systematic review of the literature was performed using PubMed, EMBASE, Cochrane Review, and gray literature databases from January 1990 through February 2019 to examine drug‐eluting implants used in CRS. Benefit‐harm assessments, value judgments, and recommendations were made based on the available evidence. Study exclusion criteria included studies unavailable in English and non‐endoscopic sinus surgeries. All authors agreed on recommendations through an iterative process.Results: Thirty‐one studies were included in the final analysis. Absorbable drug‐eluting implants achieved a high aggregate grade of evidence (A), with a recommendation for their use to be considered in carefully selected patients. Nonabsorbable drug‐eluting implants were recommended against due to minimal evidence supporting clinical efficacy. Antibiotic and alternative drug‐eluting implants lack sufficient evidence for recommendations.Conclusion: Absorbable steroid‐eluting implants are recommended for carefully selected patients with CRS. Additional research to define appropriate patient selection is needed.
- 1 June 2020
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 10 (7) , 856-870
Drug‐eluting implants in chronic rhinosinusitis: an evidence‐based review with recommendations
Background: Drug‐eluting implants are becoming increasingly popular in the treatment of chronic rhinosinusitis (CRS). A previous attempt to make an evidence‐based recommendation was hindered by limited evidence and experience with these implants. Since that time, the body of literature discussing drug‐eluting implants has grown rapidly. The objective of this study was to review drug‐eluting implants designed for use in the sinonasal cavity through an evidence‐based review with recommendations.Methods: A systematic review of the literature was performed using PubMed, EMBASE, Cochrane Review, and gray literature databases from January 1990 through February 2019 to examine drug‐eluting implants used in CRS. Benefit‐harm assessments, value judgments, and recommendations were made based on the available evidence. Study exclusion criteria included studies unavailable in English and non‐endoscopic sinus surgeries. All authors agreed on recommendations through an iterative process.Results: Thirty‐one studies were included in the final analysis. Absorbable drug‐eluting implants achieved a high aggregate grade of evidence (A), with a recommendation for their use to be considered in carefully selected patients. Nonabsorbable drug‐eluting implants were recommended against due to minimal evidence supporting clinical efficacy. Antibiotic and alternative drug‐eluting implants lack sufficient evidence for recommendations.Conclusion: Absorbable steroid‐eluting implants are recommended for carefully selected patients with CRS. Additional research to define appropriate patient selection is needed.